ANEB - Anebulo Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$6.00
DETAILS
HIGH:
$6.00
LOW:
$6.00
MEDIAN:
$6.00
CONSENSUS:
$6.00
UPSIDE:
1204.35%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | ||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | ||||||
| R&D Expenses | 4.3 | 3.5 | 5.6 | 3.0 | 2.3 | 0.1 |
| SG&A Expenses | 4.9 | 4.8 | 6.2 | 3.9 | 1.3 | 0.0 |
| Other Expenses | 0 | 0 | 0 | 0 | (0.0) | 0 |
| Operating Expenses | 9.2 | 8.3 | 11.8 | 6.8 | 3.6 | 0.2 |
| Operating Income | ||||||
| Operating Income | (9.2) | (8.3) | (11.8) | (6.8) | (3.6) | (0.2) |
| Interest Expense | 0.4 | 0.2 | 0 | 0 | 0.0 | 0.0 |
| Interest Income | 0.3 | 0.2 | 0.1 | 0.0 | 0.0 | 0 |
| Profitability | ||||||
| EBITDA | (8.1) | (7.8) | (11.7) | (6.8) | (30.2) | (0.2) |
| EBIT | (8.1) | (8.1) | (11.7) | (6.8) | (30.2) | (0.2) |
| Income Before Tax | (8.5) | (8.2) | (11.7) | (6.8) | (30.3) | (0.2) |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (8.5) | (8.2) | (11.7) | (6.8) | (30.3) | (0.2) |
| Per Share Data | ||||||
| EPS (Basic) | -0.25 | -0.32 | -0.47 | -0.29 | -1.30 | -0.01 |
| EPS (Diluted) | -0.25 | -0.32 | -0.47 | -0.29 | -1.30 | -0.01 |
| Shares Outstanding | 33.8 | 25.8 | 25.1 | 23.3 | 23.3 | 23.7 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Current Assets | ||||||
| Cash & Cash Equivalents | 11.6 | 3.1 | 11.2 | 14.5 | 20.0 | 3.0 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0.1 | 0 | 0 | 0 | 0 | 0.0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 12.0 | 3.5 | 11.7 | 15.6 | 21.7 | 3.0 |
| Non-Current Assets | ||||||
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0.2 | 0.6 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 0.2 | 0.6 | 0 | 0 | 0 | 0 |
| Total Assets | 12.1 | 4.1 | 11.7 | 15.6 | 21.7 | 3.0 |
| Current Liabilities | ||||||
| Account Payables | 0.2 | 0.2 | 0.5 | 0.4 | 0.1 | 0 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0.2 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | (0.3) | 0 | 0 | 0 | 0 | 0.0 |
| Total Current Liabilities | 0.2 | 0.3 | 1.1 | 0.5 | 0.2 | 0.2 |
| Non-Current Liabilities | ||||||
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0.3 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Liabilities | 0.3 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 0.5 | 0.3 | 1.1 | 0.5 | 0.2 | 0.2 |
| Stockholders' Equity | ||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Retained Earnings | (73.9) | (65.4) | (57.2) | (45.5) | (38.6) | (0.2) |
| Accumulated Other Comprehensive Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Stockholders' Equity | 11.7 | 3.8 | 10.6 | 15.1 | 21.4 | 2.8 |
| Total Liabilities & Equity | 12.1 | 4.1 | 11.7 | 15.6 | 21.7 | 3.0 |
| Debt Metrics | ||||||
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0.2 |
| Net Debt | (11.6) | (3.1) | (11.2) | (14.5) | (20.0) | (2.8) |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | (8.5) | (8.2) | (11.7) | (6.8) | (30.3) | (0.2) |
| Depreciation & Amortization | 0.4 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.4 | 0.8 | 0.9 | 0.5 | 0.2 | 0 |
| Change in Working Capital | 0.3 | (0.8) | 1.2 | 0.9 | (1.4) | 0.0 |
| Other Non-Cash Items | 0 | 0.2 | 0 | 0 | 26.6 | 0.0 |
| Operating Cash Flow | (6.3) | (8.1) | (9.7) | (5.4) | (4.9) | (0.2) |
| Investing Activities | ||||||
| Capital Expenditure | (0.0) | (0.0) | 0 | 0.0 | 0 | 0.0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Sales/Maturities of Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Activities | ||||||
| Net Debt Issuance | 0 | 0 | 0 | 0 | (0.2) | 0.2 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (0.3) | 0 | (0.8) | 0 |
| Financing Cash Flow | 14.9 | (0.1) | 6.4 | 0 | 21.8 | 3.2 |
| Cash Position | ||||||
| Net Change in Cash | 8.5 | (8.2) | (3.3) | (5.4) | 17.0 | 3.0 |
| Cash at Beginning | 3.1 | 11.2 | 14.5 | 20.0 | 3.0 | 0 |
| Cash at End | 11.6 | 3.1 | 11.2 | 14.5 | 20.0 | 3.0 |
| Free Cash Flow | (6.3) | (8.1) | (9.7) | (5.4) | (4.9) | (0.2) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | (9.2) | (8.3) | (11.8) | (6.8) | (3.6) | (0.2) |
| Net Income | (8.5) | (8.2) | (11.7) | (6.8) | (30.3) | (0.2) |
| EPS (Diluted) | -0.25 | -0.32 | -0.47 | -0.29 | -1.30 | -0.01 |
| Balance Sheet | ||||||
| Cash & Equivalents | 11.6 | 3.1 | 11.2 | 14.5 | 20.0 | 3.0 |
| Total Assets | 12.1 | 4.1 | 11.7 | 15.6 | 21.7 | 3.0 |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0.2 |
| Stockholders' Equity | 11.7 | 3.8 | 10.6 | 15.1 | 21.4 | 2.8 |
| Cash Flow | ||||||
| Operating Cash Flow | (6.3) | (8.1) | (9.7) | (5.4) | (4.9) | (0.2) |
| Capital Expenditure | (0.0) | (0.0) | 0 | 0.0 | 0 | 0.0 |
| Free Cash Flow | (6.3) | (8.1) | (9.7) | (5.4) | (4.9) | (0.2) |